Fortress Biotech, Inc. (FBIO): Total Liabilities
$123.36M
As of 2025-12-31
$110.63M
As of 2026-06-30
-20.4%
3-year compound annual growth
-2.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $123.36M | -15.4% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $145.87M | -12.1% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $165.94M | -32.1% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $244.28M | +43.2% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $170.63M | +25.1% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $136.41M | n/c | 2022-03-28, Balance as of period end |
| 2019-12-31 | $153.89M | +26.9% | 2021-04-09, Balance as of period end |
| 2018-12-31 | $121.25M | -3.3% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $125.45M | +42.9% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $87.76M | +155.6% | 2018-03-16, Balance as of period end |
| 2015-12-31 | $34.34M | +82.6% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $18.80M | -2.6% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $19.30M | +1.8% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $18.96M | +346.8% | 2014-03-14, Balance as of period end |
| 2011-12-31 | $4.24M | +172.2% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $1.56M | n/a | 2012-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $123.36M | -15.4% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $216.01M | -12.8% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
Compare FBIO, NUVB, TNGX, ENTA side by side · Screen every company in Pharmaceutical Preparations ↗